Tag: Poxel
Poxel: titer rises, orphan drug designation – 01/25/2023 at 11:30 am
(CercleFinance.com) – Poxel stock recorded one of the strongest rises in the CAC Mid & Small index on Wednesday after obtaining orphan drug designation from the European Commission for the…
Poxel: looking for additional funding – 12/23/2022 at 15:57
(CercleFinance.com) – Poxel announced on Thursday evening that it had drawn down the last two tranches of its equity financing line concluded with Iris Capital Investment. This drawdown, for a…
Poxel: looking for additional funding
(CercleFinance.com) – Poxel announced on Thursday evening that it had drawn down the last two tranches of its equity financing line concluded with Iris Capital Investment. This drawdown, for a…
Poxel Presents Phase II (DESTINY-1) Results of PXL065 for the Treatment of NASH at AASLD The Liver Meeting® 2022 – 11/07/2022 8:15 PM
– “Late-breaking abstract” selected by the AASLD as one of the best of the 2022 edition (“Best of the Liver Meeting”) – The phase II study of PXL065 for the…
Poxel: a broker adjusts
By Claude Leguilloux Published on 07/10/2022 at 15:56 Photo credit © Poxel (Boursier.com)…
Analyst recommendations: Renault, Actia Group, Kering, Bureau Veritas, Legrand, Ubisoft, Poxel, Maisons du Monde
For this last session of the week, Oddo BHF raises its recommendation on the car manufacturer Renault. A few changes in the target price should be highlighted, particularly for the…
Poxel Obtains Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for PXL770 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) – 03/10/2022 at 07:30
• Preclinical studies have demonstrated the potential of PXL770 for Phase II development in the treatment of ADPKD • Efficacy data from preclinical studies confirm the interest of the strategic…
Poxel: Degroof Petercam places its objective under review
(CercleFinance.com) – Degroof Petercam announced on Tuesday that it has placed its price target on Poxel under review following the presentation of positive results from a phase II study in…
After these positive results, the Poxel bet is even more tempting
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? Sale ? What course objective? Our experts engage and…
Poxel: pause
By Jean-Baptiste André Published on 08/11/2022 at 4:28 p.m. Photo credit © Poxel …
Analyst recommendations: Crédit Agricole, Ubisoft, Arkema, Sensorion, Poxel, Nanobiotix, Inventiva
Jefferies is very active this Thursday morning, with a review of stocks in the health sector, in particular biotechs. Analyst recommendations: Crédit Agricole, Ubisoft, Arkema, Sensorion, Poxel, Nanobiotix, Inventiva |…
Poxel: end of series after announcements
By Jean-Baptiste André Published on 08/08/2022 at 09:26 Photo credit © Poxel (Boursier.com)…